Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Clozaril Articles

1992 NET PROFITS SURGE 34% AT SANDOZ

5 April 1993

CLOZAPINE RATIONING

22 March 1993

SANDOZ 1992 SALES SEE 8% INCREASE

1 February 1993

ZENECA'S PROMISING R&D PIPELINE PRESENTED

14 December 1992

EUROPE STOCK COMMENT

7 December 1992

COUNTING THE COST OF SCHIZOPHRENIA

7 December 1992

CLOZARIL CHANGES D2 ANTAGONIST THEORY

3 August 1992

Sandoz schizophrenia therapy

6 July 1992

"STRINGS" WITH US ACCELERATED APPRO

27 April 1992

BROKER UPGRADES SWISS DRUG MAJORS

20 April 1992

FOCUS ON JANSSEN'S RISPERDOL

16 March 1992

ANALYST R&D UPDATE FROM ICI

6 January 1992

Showing 101-112 of 112 articles

Go to beginningPrevious
  • 1
  • 2
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS